Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Passes Below 200 Day Moving Average – Should You Sell?

by · The Cerbat Gem

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $24.69 and traded as low as $17.66. Arcturus Therapeutics shares last traded at $17.73, with a volume of 330,986 shares.

Analyst Ratings Changes

Several equities analysts have weighed in on ARCT shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Tuesday, October 1st. Leerink Partners started coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 price objective for the company. Finally, Leerink Partnrs raised Arcturus Therapeutics to a “strong-buy” rating in a research report on Monday, August 12th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $71.40.

Get Our Latest Research Report on Arcturus Therapeutics

Arcturus Therapeutics Stock Up 1.5 %

The stock has a market cap of $484.74 million, a price-to-earnings ratio of -7.00 and a beta of 2.61. The stock has a fifty day moving average of $20.86 and a two-hundred day moving average of $24.56.

Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.85) by $1.21. Arcturus Therapeutics had a negative return on equity of 25.47% and a negative net margin of 41.21%. The firm had revenue of $49.86 million for the quarter, compared to analysts’ expectations of $21.00 million. During the same quarter last year, the firm earned ($1.98) earnings per share. Equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 EPS for the current fiscal year.

Insider Activity at Arcturus Therapeutics

In related news, COO Pad Chivukula sold 12,000 shares of Arcturus Therapeutics stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the transaction, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 15.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new stake in shares of Arcturus Therapeutics during the first quarter worth about $40,000. nVerses Capital LLC purchased a new stake in shares of Arcturus Therapeutics during the third quarter worth about $42,000. Quest Partners LLC increased its position in shares of Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 3,579 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its position in shares of Arcturus Therapeutics by 10.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 428 shares during the last quarter. Finally, Public Employees Retirement System of Ohio increased its position in shares of Arcturus Therapeutics by 63.8% during the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 1,800 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

(Get Free Report)

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

Featured Articles